| Watchedfields: | changed |
| Verifiedrevid: | 443395760 |
| Iupac Name: | (±)-N-Carbamoyl-2-propan-2-ylpent-4-enamide |
| Width: | 150px |
| Chirality: | Racemic mixture |
| Routes Of Administration: | Oral |
| Excretion: | Renal |
| Cas Number: | 528-92-7 |
| Atc Prefix: | N05 |
| Atc Suffix: | CM12 |
| Pubchem: | 10715 |
| Chemspiderid: | 10264 |
| Unii: | V18J24E25E |
| Kegg: | D03975 |
| Chembl: | 509282 |
| C: | 9 |
| H: | 16 |
| N: | 2 |
| O: | 2 |
| Smiles: | O=C(NC(=O)N)C(C(C)C)C\C=C |
| Stdinchi: | 1S/C9H16N2O2/c1-4-5-7(6(2)3)8(12)11-9(10)13/h4,6-7H,1,5H2,2-3H3,(H3,10,11,12,13) |
| Stdinchikey: | KSUUMAWCGDNLFK-UHFFFAOYSA-N |
Apronal (brand name Sedormid), or apronalide, also known as allylisopropylacetylurea or allylisopropylacetylcarbamide, is a hypnotic/sedative drug of the ureide (acylurea) group synthesized in 1926[1] by Hoffmann-La Roche. Though it is not a barbiturate, apronalide is similar in structure to the barbiturates (being an open-chain carbamide instead of having a heterocyclic ring).[2] In accordance, it is similar in action to the barbiturates, although considerably milder in comparison (formerly used as a daytime sedative at doses of 1 to 2 grams every 3 to 4 hours). Upon the finding that it caused patients to develop thrombocytopenic purpura, apronalide was withdrawn from clinical use.[3]
Medicines with allylisopropylacetylurea are no longer used except in Japan. Notably Australian Therapeutic Goods Administration issued a safety alert in May 2023 which prohibits the sale, supply and use of Japanese EVE-branded products in Australia[4] due to its dangerous side effects.